Eli Lilly enters strike mode ahead of pivotal Alzheimer's, diabetes launches, CFO says

Alongside its late-stage testing efforts in Alzheimer's disease, Lilly is taking steps to ensure its investigational drug donanemab gets off to a smoother start than its would-be rival, Biogen’s Aduhelm. For one, the Indianapolis-based pharma is working to build out an infusion and diagnostic infrastructure to forge a more efficient “ecosystem” for patients, Ashkenazi said.

Importantly, Lilly has also thrown down the gauntlet with a head-to-head trial against Aduhelm, also known as aducanumab. Data from that study are expected by the middle of next year, Ashkenazi said.